Teaching cancer patients undergoing chemotherapy in the National Health Service to use daily self-moxibustion to reduce chemotherapy-induced pancytopenia: a feasibility study

Abstract

Introduction Cancer patients receiving myelosuppressive chemotherapy risk developing chemotherapy-induced pancytopenia (neutropenia, anemia, thrombocytopenia) with possible negative impact on survival due to dose delays or reductions. Moxibustion, the use of heat to stimulate acupuncture points, is a traditional East Asian intervention that may have potential to reduce pancytopenia. This study explored the feasibility of teaching chemotherapy patients in a National Health Service (NHS) cancer center a 10-minute daily intervention. It also aimed to obtain preliminary data to assess the completion of chemotherapy according to both dosage and schedule and assess any reduction of chemotherapy toxicities. Methods This uncontrolled, single-arm study aimed to recruit breast, colorectal or gynecological cancer patients undergoing chemotherapy regimens for which granulocyte-colony stimulating factor (G-CSF) is not indicated. The primary outcome was concordance with daily self-administered moxibustion (starting 7‒10 days before commencing chemotherapy and continuing for three weeks after the final cycle) measured by daily moxibustion diaries. Secondary measures included blood counts, variation to planned chemotherapy schedule, health-related quality of life measured by functional assessment of cancer therapy (FACT)-general, FACT-anemia, and FACT-neutropenia, patient activation measure (PAM-13), chemotherapy-related toxicities, and adverse events of moxibustion. Results Twenty-five participants were recruited. Of a potential 2944 applications, 1369 were recorded; overall concordance rate was 46.5% (individual range 4%‒96%). Main reasons for non-concordance included chemotherapy-related sickness, fatigue, and forgetfulness. There were no serious adverse events. The intervention was acceptable to some patients and oncology healthcare professionals. Challenges to collecting and analyzing data using the outcome measures were identified. Conclusion This was the first known attempt in the West to research using self-applied moxibustion in a conventional cancer care setting. The results indicate this intervention is generally acceptable and that it is possible to recruit to a study. The challenges identified inform recommendations for future study design.

Keywords

cancer / moxibustion / chemotherapy / integrative oncology / self-care / neutropenia / anemia / thrombocytopenia

References

[1] Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev. 2022; 109:102427.

[2] Lyman GH. Febrile neutropenia: an ounce of prevention or a pound of cure. J Oncol Pract. 2019; 15(1):27-29.

[3] Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017; 120:163-179.

[4] Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist. 2022; 27(8):625-636.

[5] Crawford J, Herndon D, Gmitter K, Weiss J. The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncol. 2024; 20(21):1515-1530.

[6] Lyman G, Dale D, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003; 21:4524-4531.

[7] Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100(2):228-237.

[8] Gascón P, Awada A, Karihtala P, Lorenzen S, Minichsdorfer C. Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment. Wien Klin Wochenschr. 2024; 136(11):362-368.

[9] Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27:v111-v118.

[10] Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011; 47(1):8-32.

[11] Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015; 33(28):3199-3212.

[12] Lapidari P, Vaz-Luis I, Di Meglio A. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review. Crit Rev Oncol. 2021; 157:103193.

[13] Cybulska P, Goss C, Tew WP, Parameswaran R, Sonoda Y. Indications for and complications of transfusion and the management of gynecologic malignancies. Gynecol Oncol. 2017; 146(2):416-426.

[14] Kumagai S, Sugiyama T, Shoji T, et al. Does severe anemia caused by dose-dense paclitaxel-carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial. Int J Gynecol Cancer. 2011; 21(9):1585-1591.

[15] Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009; 31: 2416-2432.

[16] Zhang HW, Lin ZX, Cheung F, Cho WC, Tang JL. Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer. Cochrane Database Syst Rev. 2018; 2018(11):CD010559.

[17] Lu S, Wang B, Wang J, et al. Moxibustion for the treatment of cancer and its complications: efficacies and mechanisms. Integr Cancer Ther. 2023; 22: 15347354231198089.

[18] Xue D, Lan RL, Hu HT, Zhang YB, Huang XB. Moxibustion for chemotherapy-induced myelosuppression: a systematic review. World J Acupunct Moxibust. 2025. doi:10.1016/j.wjam.2025.12.001.

[19] Bae HR, Kim EJ, Ahn YC, Cho JH, Son CG, Lee NH. Efficacy of moxibustion for cancer-related fatigue in patients with breast cancer: a systematic review and meta-analysis. Integr Cancer Ther. 2024; 23: 15347354241233226.

[20] Wang XQ, Qiao Y, Duan PB, Du SZ, Yang LH. Efficacy and safety of moxibustion on cancer-related fatigue: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2023; 31(9):508.

[21] Huang Z, Qin Z, Yao Q, Wang Y, Liu Z. Moxibustion for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Evid Based Complement Altern Med. 2017; 2017:9854893.

[22] Yao Z, Xu Z, Xu T, et al. Moxibustion for alleviating chemotherapy-induced gastrointestinal adverse effects: a systematic review of randomized controlled trials. Complement Ther Clin Pract. 2022; 46:101527.

[23] Li Y, Hong E, Ye W, You J. Moxibustion as an adjuvant therapy for cancer pain: a systematic review and meta-analysis. J Pain Res. 2023; 16:515-525.

[24] Sagar SM, Wong RK. Safety and side effects of acupuncture and moxibustion as a therapy for cancer. In: Cho W ed. Acupuncture and Moxibustion as an Evidence-Based Therapy for Cancer. Dordrecht, Netherlands: Springer; 2012: 265-289.

[25] Li ZY, Chen CL, Li XY, et al. Comparative efficacy of moxibustion in chemotherapy-induced leukopenia: a Bayesian network meta-analysis. Integr Med Res. 2025; 14(2):101145.

[26] de Valois B, Young T, Glynne-Jones R, Scarlett C, Staebler F. Limiting chemotherapy side effects by using moxa. Eur J Orient Med. 2016; 8(8):29-39.

[27] WMA Declaration of Helsinki: ethical principles for medical research involving human participants. World Medical Association web site. https://www.wma.net/policies-post/wma-declaration-of-helsinki/. Accessed August 17, 2025. 2025.

[28] Cheng CW, Fu SF, Zhou QH, et al. Extending the CONSORT statement to moxibustion. J Integr Med. 2013; 11(1):54-63.

[29] Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for designing and evaluating feasibility pilot studies. Med Care. 2022; 60(1):95-103.

[30] Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016; 25(3):1057-1073.

[31] Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021; 26(9):e1609-e1618.

[32] Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990; 8(12):1935-1937.

[33] Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004; 22(21):4302-4311.

[34] Wonders KY, Schmitz K, Harness J. Dose delays, dose reductions, and relative total dose intensity in patients with advanced cancer who exercised during neoadjuvant chemotherapy treatment. Integr Cancer Ther. 2023; 22: 15347354231168368.

[35] Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11(3):570-579.

[36] Wagner LI, Beaumont JL, Ding B, et al. Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the functional assessment of cancer therapy-neutropenia (FACT-N). Support Care Cancer. 2008; 16(1):47-56.

[37] Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. Jul 1997; 34(3Suppl 2): 13-19.

[38] Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005; 40:1918-1930.

[39] Knoerl R, Berry D, Meyerhardt JA, et al. Identifying participants’ preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis. Support Care Cancer. 2022; 30(12):9963-9973.

[40] Deadman P, Al-Khafaji M, Baker K. A Manual of Acupuncture. 2nd ed. Hove, UK: Journal of Chinese Medicine Publications; 2007.

[41] Staebler F. The daily use of moxibustion to treat chemotherapy-induced bone marrow depression: a practical evaluation based on 20 years of clinical experience. J Chin Med. 2009; 90:65-70.

[42] Roesel I, Froehlich D, Joos S, Valentini J, Mauch H, Martus P. The patient activation measure-13 (PAM-13) in an oncology patient population: psychometric properties and dimensionality evaluation. Health Qual Life Outcomes. 2024; 22(1):39.

[43] Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984; 2(11):1281-1288.

[44] Lakkunarajah S, Breadner DA, Zhang H, Yamanaka E, Warner A, Welch S. The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis. Curr Oncol. 2021; 28(5):4031-4041.

[45] Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018; 91(9):403-413.